Accreditation Information

Direct Accreditation:

            Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Boston University School of Medicine designates this  live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives

1. Identify gaps in knowledge relating to rheumatologic dermatology diseases
2. Collaborate and communicate effectively with other disciplines regarding patient care issues
3. Cite and discuss evidence-based literature pertaining to the pathogenesis, physical examination, and/or management of complex rheumatologic dermatology patients

Target Audience

Rheumatologists
Dermatologists
Trainees from both disciplines

Faculty Disclosure

Faculty, Planning Committee and CME Administrator disclosure statement: 

Justin Bucci, Speaker, has no relevant financial relationships to disclose

Christina Lam, Course Director and Planning Committee, has no relevant financial relationships to disclose

Eugene Kissin, Co-Course Director and Planning Committee, has no relevant financial relationships to disclose

Sakina Flint, RSS Coordinator,  has no relevant financial relationships to disclose

Faculty disclosure of off-label use:

Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.

Faculty disclosure policy:

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.